DVAX – Despite the deficiency in IP, DVAX may be able to exploit the rivalry between GSK and MRK to get one of them to bid for the rights to Heplisav. Whichever company does not deal with DVAX could end up with no market in due course. Of course, the numbers at risk are pretty small for companies the size of GSK and MRK, so they could opt to do nothing.
Market Data 
Markets 
AI
